NASDAQ:IMMP Immutep (IMMP) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free IMMP Stock Alerts $2.82 +0.13 (+4.83%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$2.73▼$2.8950-Day Range$2.20▼$2.8952-Week Range$1.50▼$3.90Volume315,670 shsAverage Volume300,889 shsMarket Capitalization$247.96 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immutep alerts: Email Address Immutep MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside201.4% Upside$8.50 Price TargetShort InterestBearish1.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.06Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.31) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.00 out of 5 starsMedical Sector4477th out of 5,424 stocksPharmaceutical Preparations Industry2095th out of 2,550 stocks 3.5 Analyst's Opinion Consensus RatingImmutep has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmutep has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.66% of the outstanding shares of Immutep have been sold short.Short Interest Ratio / Days to CoverImmutep has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Immutep has recently increased by 15.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmutep does not currently pay a dividend.Dividend GrowthImmutep does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMMP. Previous Next 2.2 News and Social Media Coverage News SentimentImmutep has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Immutep this week, compared to 1 article on an average week.Search Interest4 people have searched for IMMP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Immutep to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immutep insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.07% of the stock of Immutep is held by insiders.Percentage Held by InstitutionsOnly 2.32% of the stock of Immutep is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immutep are expected to decrease in the coming year, from ($0.31) to ($0.32) per share.Price to Book Value per Share RatioImmutep has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Immutep Stock (NASDAQ:IMMP)Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Read More IMMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMMP Stock News HeadlinesMay 3, 2024 | americanbankingnews.comImmutep (NASDAQ:IMMP) Shares Cross Above 50-Day Moving Average of $2.49May 2, 2024 | globenewswire.comPositive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue SarcomaMay 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. May 1, 2024 | seekingalpha.comImmutep: Realizing The Expected Catalysts, With More To ComeApril 29, 2024 | globenewswire.comImmutep Quarterly Activities Report Q3 FY24April 26, 2024 | markets.businessinsider.comImmutep’s Efti Shows Promise in Cancer Therapy, Analyst Maintains Buy RatingApril 25, 2024 | markets.businessinsider.comImmutep Buy Rating Justified by Strong Clinical Trial Results and Promising Future ProspectsApril 25, 2024 | americanbankingnews.comImmutep (NASDAQ:IMMP) Stock Passes Below 50 Day Moving Average of $2.45May 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 24, 2024 | markets.businessinsider.comImmutep Reports Positive Preliminary Topline Results From TACTI-003 Cohort BApril 24, 2024 | msn.comImmutep reports promising efti/Keytruda data for head and neck cancerApril 24, 2024 | globenewswire.comImmutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort BApril 19, 2024 | finance.yahoo.comMutual Fund Series Trust - Alphacentric Municipal Opportunities Fund (MUNIX)April 18, 2024 | globenewswire.comImmutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761April 17, 2024 | globenewswire.comImmutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerMarch 7, 2024 | edition.cnn.comImmutep Ltd Sponsored ADRFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immutep on Strong Clinical Pipeline and Market PotentialJanuary 4, 2024 | finance.yahoo.comFirst Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial CancerJanuary 3, 2024 | seekingalpha.comImmutep: Upcoming Signals For 2024 (Maintain Buy)December 24, 2023 | finance.yahoo.comImmutep Limited (IMMP)November 6, 2023 | finance.yahoo.comImmutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast CancerNovember 3, 2023 | finanznachrichten.deImmutep Limited: Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNovember 3, 2023 | markets.businessinsider.comImmutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNovember 2, 2023 | finance.yahoo.comImmutep to Participate in November Investor EventsOctober 27, 2023 | markets.businessinsider.comBuy Rating for Immutep (IMMP) Supported by Strong Phase 2 Study Results and Solid Financial PositionOctober 25, 2023 | msn.comImmutep receives about A$1.13M R&D tax incentive from Australian govtOctober 25, 2023 | finance.yahoo.comImmutep receives ~A$1.13 million R&D Tax IncentiveSee More Headlines Receive IMMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/04/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMMP CUSIPN/A CIK1506184 Webwww.immutep.com Phone(128) 315-7003Fax61-2-8569-1880Employees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+201.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio17.24 Quick RatioN/A Sales & Book Value Annual Sales$3.50 million Price / Sales70.85 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book2.71Miscellaneous Outstanding Shares87,930,000Free Float85,231,000Market Cap$247.96 million OptionableOptionable Beta2.10 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Marc Voigt (Age 51)CEO, MD, CFO, Chief Business Officer & Executive Director Comp: $365.93kMs. Deanne Miller LLB (Age 47)COO, General Counsel & Joint Company Secretary Comp: $239.3kDr. Frederic Triebel M.D. (Age 69)Ph.D., Chief Scientific Officer & Executive Director Comp: $292.11kMr. Christian Mueller BBAMSc., Senior Vice President of Regulatory & StrategyMr. Florian D. Vogl M.D.M.Sc., Ph.D., Chief Medical OfficerMs. Indira NaiduJoint Company SecretaryMore ExecutivesKey Competitors2seventy bioNASDAQ:TSVTAldeyra TherapeuticsNASDAQ:ALDXXBiotechNASDAQ:XBITFoghorn TherapeuticsNASDAQ:FHTX23andMeNASDAQ:MEView All CompetitorsInstitutional OwnershipBNP Paribas Financial MarketsBought 4,700 shares on 5/1/2024Ownership: 0.040%PFG Investments LLCBought 51,000 shares on 4/22/2024Ownership: 0.058%Meridian Wealth Management LLCBought 11,250 shares on 2/8/2024Ownership: 0.367%View All Institutional Transactions IMMP Stock Analysis - Frequently Asked Questions Should I buy or sell Immutep stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMMP shares. View IMMP analyst ratings or view top-rated stocks. What is Immutep's stock price target for 2024? 1 analysts have issued 12-month target prices for Immutep's shares. Their IMMP share price targets range from $7.00 to $10.00. On average, they expect the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 201.4% from the stock's current price. View analysts price targets for IMMP or view top-rated stocks among Wall Street analysts. How have IMMP shares performed in 2024? Immutep's stock was trading at $2.40 at the start of the year. Since then, IMMP shares have increased by 17.5% and is now trading at $2.82. View the best growth stocks for 2024 here. Are investors shorting Immutep? Immutep saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,260,000 shares, an increase of 10.5% from the March 15th total of 1,140,000 shares. Based on an average trading volume of 141,400 shares, the days-to-cover ratio is currently 8.9 days. View Immutep's Short Interest. What other stocks do shareholders of Immutep own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT). Who are Immutep's major shareholders? Immutep's stock is owned by a variety of retail and institutional investors. Top institutional investors include PFG Investments LLC (0.06%) and BNP Paribas Financial Markets (0.04%). How do I buy shares of Immutep? Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMMP) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe asset beating inflation by 4xColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
